CD24 Platform
Pioneering a novel checkpoint inhibitor
What is CD24?
CD24 is a cell-surface protein that is an important checkpoint for tumor immune response. CD24 is overexpressed in approximately 70% of human cancers, making it a promising checkpoint to target.1 However, targeting CD24 on cancer-specific cells remains a challenge because it is also expressed in normal tissues.
1. Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cell Mol Immunol. 2010 Mar;7(2):100-3. doi: 10.1038/cmi.2009.119.
Our CD24 approach
Our cancer-specific antibody targets a neo-CD24 epitope that is exposed only on cancer cells.
Our platform broadly targets cancers with CD24 mutations across solid and liquid tumors. Our multi faceted approach includes a range of treatment modalities to provide the right tool to fight cancer.
Our antibody shows broad reactivity to hepatocellular carcinoma, breast cancer, ovarian cancer, cervical cancer, neuroblastoma, prostate cancer, lung cancer, and many types of malignant brain tumors.
See how we turn our science into action.